VistaGen Therapeutics, Inc. Overview
Pro stress-test →VistaGen is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. The pherine pipeline currently consists of five investigational product candidates focused on improving the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause.
Strategic Profile
Pro stress-test →The company is at a critical juncture following setbacks in its lead program. PALISADE-3 did not meet its primary endpoint, though randomized safety data were favorable. The company expects topline randomized results from the PALISADE-4 Phase 3 trial of fasedienol in the first half of 2026, making this duplicative trial crucial for determining its future viability.
Competitive Landscape
Pro stress-test →VistaGen's pherine approach represents a novel mechanism for treating anxiety and mood disorders. Competitors in the acute anxiety space include traditional pharmaceuticals like benzodiazepines and newer agents from companies developing rapid-onset treatments. The company's intranasal, non-systemic approach differentiates it if successfully developed, though its lead program's clinical failure creates competitive uncertainty.
Industry Context
VistaGen Therapeutics, Inc. operates in Biopharmaceuticals - Neuroscience/Psychiatry.
Key facts
Founded: 2007 · Headquarters: South San Francisco, California · Revenue: $0 · Market cap: N/A